Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, provides an overview of the trial design and rationale of the randomized, open-label Phase III trial (NCT04662255) of pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, in patients with relapsed mantle cell lymphoma (MCL). Initial clinical data has shown pirtobrutinib to be as efficacious and safe as existing BTK inhibitors with fewer adverse events including neutropenia, and atrial fibrillation. In this trial, BTK inhibitor naïve patients will either receive pirtobrutinib, or existing BTK inhibitors including ibrutinib, acalabrutinib, or zanubrutinib. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

свернуть